Comparing Standard and High Dose Stereotactic Body Radiation Therapy Versus Conventional External Beam Radiation for Spine Metastatic Cancer
A Multicenter Randomized Phase II Study
Led by University of Oklahoma · Updated on 2025-10-20
240
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are comparing three types of radiation therapy for cancer that has spread to the spine, focusing on how well these treatments reduce pain and improve pain-free rates. Metastatic spine cancer is becoming more common as patients live longer, and current standard treatment with external beam radiation therapy EBRT has limited long-term pain control. This study aims to evaluate standard dose stereotactic body radiation therapy SBRT, higher dose SBRT, and conventional EBRT to determine which approach provides more durable pain relief for patients with spine metastases.
Participants will be randomly assigned to one of three treatment groups standard dose SBRT receiving 24 Gray in 2 fractions, high dose SBRT receiving 19 Gray in 1 fraction, or conventional EBRT receiving 8 Gray in 1 fraction. Each participant will receive the assigned radiation therapy as part of their standard care. Questionnaires assessing pain Brief Pain Inventory, quality of life COST-FACIT, EuroQol EQ-5D will be completed at the start and at 3, 6, 9, and 12 months after treatment to monitor effects and outcomes.
Throughout the study, participants will be evaluated using these questionnaires to measure pain freedom at 3 months as the primary outcome, with additional assessments at 6 and 12 months including local tumor control, vertebral compression fractures, and progression-free survival. The study includes follow-up visits between 3 to 12 months after treatment to monitor symptoms and quality of life. The overall goal is to better understand which radiation therapy approach offers the most effective and lasting pain relief for patients with metastatic spine cancer.
CONDITIONS
Brief Title
Spine Radiosurgery for Symptomatic Metastatic Neoplasms
Research Team
L
Lead Onco Nurse
S
Shearwood McClelland III, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
SBRT (24 Gy in 2 fractions)
SBRT (19 Gy in 1 fraction)
Conventional EBRT (8 Gy in 1 fraction)
Typical palliative EBRT
What it is
Stereotactic body radiotherapy delivering 24 Gy over two sessions
Stereotactic body radiotherapy delivering 19 Gy in one session
Conventional external beam radiotherapy delivering 8 Gy in one session
Standard palliative EBRT (such as single‑fraction 8 Gy) is the usual treatment for pain relief in spinal metastases
Role in trial
Investigational SBRT regimen being tested
Investigational SBRT regimen being tested
Control arm using conventional EBRT
Represents commonly used palliative radiation outside of trial
Primary use
To relieve pain from spinal metastases
To relieve pain from spinal metastases
To relieve pain from spinal metastases
To reduce pain from spinal metastases in routine clinical practice
How it is given or performed
SBRT given in two sessions totaling 24 Gy
SBRT given in a single session of 19 Gy
One session of 8 Gy conventional radiation
Typically single‑fraction cEBRT such as 8 Gy delivered in one session
Evidence status
Evaluated in this randomized trial; efficacy not yet established
Evaluated in this randomized trial; efficacy not yet established
Evaluated in this randomized trial; efficacy not yet established in this study context
cEBRT has low reported complete pain response rates (~10‑20%) in published trials
Important risks
Not yet established within this study
Not yet established within this study
Not yet established within this study
Conventional EBRT is generally well tolerated with few adverse effects
Important limitations
Dose regimens are experimental and have unknown comparative efficacy and safety
Single‑fraction high dose approach is investigational and its benefit over standard SBRT is unproven
Single‑fraction 8 Gy may offer limited duration of pain relief compared to SBRT regimens
Conventional EBRT often provides short‑lived pain relief and lower complete response rates compared to SBRT in meta‑analyses
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Participant must have histologic confirmation of malignancy and spinal metastatic disease confirmed by imaging.
Participant must have received no prior therapies for this disease, including previous radiation therapy to the treatment site.
Age greater than 18 years.
Life expectancy of at least 3 months as documented by the investigator.
Worst pain score less than 2 of 10 according to the Brief Pain Inventory.
No intention to change pain medications on the first day of stereotactic body radiation therapy (SBRT).
Spinal Instability score (SINS) of 12 or less.
Participant must be a candidate for spine SBRT per Radiation Oncology.
Ability to understand and willingness to sign informed consent.
You will not qualify if you...
Receiving any other investigational agents.
Prognosis less than 3 months.
Uncontrolled intercurrent illness including active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness/social situations limiting compliance.
Pregnant or nursing participants.
Unable to receive MRI of the spine.
Spinal Instability in Neoplasia score (SINS) greater than or equal to 12.
Previous stereotactic radiosurgery overlapping the current treatment field.
More than 3 consecutive vertebral bodies in the SBRT treatment volume.
Not a candidate for SBRT per radiation oncology discretion.
Known primary cancer with estimated median survival 3 months or less.
Unknown primary cancer.
Brief Pain Inventory score greater than 2.
Previous radiation therapy involving the intended SBRT treatment field.
Previous spinal surgery involving the SBRT target volume (biopsy excluded).
Neurological deficits from malignant cauda equina compression or epidural spinal cord compression.
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 1 week
Participants receive one of three types of radiation therapy: standard dose SBRT (24 Gy in 2 fractions), high dose SBRT (19 Gy in 1 fraction), or conventional EBRT (8 Gy in 1 fraction).
1 to 2 visits depending on treatment arm
Follow-up
Duration - 3 to 12 months
Participants complete follow-up questionnaires and assessments to evaluate pain control and treatment effects.
Visits at 3, 6, 9, and 12 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Open-label Phase 1 Study Evaluating Safety and Dosage of MK-8294 in Advanced Solid Tumors
Comparing Standard and High Dose Stereotactic Body Radiation Therapy Versus Conventional External Beam Radiation for Spine Metastatic Cancer
A Multicenter Randomized Phase II Study
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Establishing a Protocol to Increase Racial/Ethnic Under-Represented Minority Enrollment on an Active Radiation Oncology Multicenter Randomized Clinical Trial.
Ulysses G Gardner, Otis W Brawley, Elizabeth E Obi...